Pinnix Chelsea C, Andraos Therese Y, Milgrom Sarah, Fanale Michelle A
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Curr Hematol Malig Rep. 2017 Jun;12(3):251-256. doi: 10.1007/s11899-017-0386-x.
The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome. For some patients, delay of therapy to the postpartum period is feasible.
对孕妇淋巴瘤的诊断带来了治疗挑战,需要在不影响对母亲有治愈潜力的治疗的情况下考虑发育中的胎儿。孕期开始治疗的决定受到胎儿、母亲和疾病相关因素的严重影响,其中最具影响力的是诊断时的孕周、疾病分期、侵袭性以及是否存在危及生命的症状。近期数据表明,如果认为推迟治疗不会影响母亲的预后,那么将治疗推迟到孕早期之后是可取的。对于一些患者来说,将治疗推迟到产后阶段是可行的。